Amplia halts recruitment in AMPLICITY trial

Amplia has announced the strategic decision to halt further recruitment in AMPLICITY following three dose-limiting toxicities associated with the chemotherapy regimen FOLFIRINOX used in the study. No toxicity concerns have been identified regarding narmafotinib. 

Given this challenge with FOLFIRINOX, and Amplia's anticipation of an increasing preference for less toxic chemotherapeutic regimens in clinical practice, future studies of narmafotinib in pancreatic cancer will focus on combinations with less toxic chemotherapy or targeted drugs. 

Amplia's ongoing study of narmafotinib in pancreatic cancer, ACCENT, has continued to produce highly promising data, as recently shared. 

Click to read the ASX announcement.